search
Back to results

Islet Transplantation Using Campath-1H and Infliximab Induction

Primary Purpose

Type 1 Diabetes

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
alemtuzumab
islet transplant
infliximab
Sponsored by
University of Alberta
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 1 Diabetes focused on measuring islet, transplantation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: must have Type 1 diabetes mellitus for more than 5 years diabetes must be complicated by at least one of the following situations that persist despite intensive insulin management efforts. The complicating situations are (1) Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels of < 3.0 mmol/L; (2) Metabolic lability/instability, characterized by MAGE ≥ 11.0 mmol/L and wide swings in blood glucose despite optimal diabetes therapy; and (3) Despite efforts at optimal glucose control, progressive secondary complications of diabetes, including retinopathy, neuropathy, or nephropathy Exclusion Criteria: Severe co-existing cardiac disease Active alcohol or substance abuse Psychiatric disorder making the subject not a suitable candidate for transplantation Active infection including hepatitis C, hepatitis B, HIV, or TB Any history of or current malignancies except squamous or basal skin cancer BMI > 28 kg/m2 or body weight > 85 kg at screening visit Positive fasting C-peptide response on assessment (2 positive results) Creatinine clearance < 80 mL/min/1.73 m2 Serum creatinine > 150 µmol/L Macroalbuminuria (urinary albumin excretion rate > 300 mg/24h) Baseline Hb < 105g/L in women, or < 130 g/L in men Baseline LFT's outside of normal range Untreated proliferative retinopathy Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast feeding Previous transplant, or evidence of sensitization on PRA Insulin requirement > 1.0 IU/kg/day HbA1C > 0.12 Hyperlipidemia (fasting LDL cholesterol > 3.4 mmol/L, treated or untreated; and/or fasting triglycerides > 2.3 mmol/L) Under treatment for a medical condition requiring chronic use of steroids Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR > 1.5 Untreated Addison's disease Untreated Celiac disease Untreated thyroid disease

Sites / Locations

  • University of Alberta - Clinical Islet Transplant Program

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
September 12, 2005
Last Updated
October 1, 2009
Sponsor
University of Alberta
Collaborators
Juvenile Diabetes Research Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00175266
Brief Title
Islet Transplantation Using Campath-1H and Infliximab Induction
Official Title
Islet Transplantation in Type 1 Diabetic Patients Using Campath-1H and Infliximab Induction
Study Type
Interventional

2. Study Status

Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
University of Alberta
Collaborators
Juvenile Diabetes Research Foundation

4. Oversight

5. Study Description

Brief Summary
Islet transplantation has been investigated as a treatment for Type 1 diabetes mellitus in selected patients with inadequate glucose control despite insulin therapy. However, the perennial hope that such an approach would result in long-term freedom from the need for exogenous insulin, with stabilization of the secondary complications of diabetes, has failed to materialize in practice. The goal of the present study is therefore to improve the safety and efficacy of clinical islet-alone transplantation by minimizing dependence on calcineurin-inhibitor therapy - thereby avoiding potential nephrotoxicity, and furthermore improving success with single-donor islet infusions by avoiding all diabetogenic immunosuppression. Campath-1H, combined with Infliximab induction therapy provides a unique opportunity to minimize dosing of maintenance long-term immunosuppression while further promoting islet engraftment.
Detailed Description
This is a single-centre, prospective, open-label study in Type 1 diabetic participants receiving an islet cell transplant; all participants will receive Campath-1H + Infliximab induction therapy followed by sirolimus and ultra-low dose tacrolimus maintenance therapy. The primary objective of this protocol is to assess the safety of this treatment regimen in adult Type 1 diabetic participants receiving their first islet transplant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
islet, transplantation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
alemtuzumab
Intervention Type
Procedure
Intervention Name(s)
islet transplant
Intervention Type
Drug
Intervention Name(s)
infliximab

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: must have Type 1 diabetes mellitus for more than 5 years diabetes must be complicated by at least one of the following situations that persist despite intensive insulin management efforts. The complicating situations are (1) Reduced awareness of hypoglycemia, as defined by the absence of adequate autonomic symptoms at plasma glucose levels of < 3.0 mmol/L; (2) Metabolic lability/instability, characterized by MAGE ≥ 11.0 mmol/L and wide swings in blood glucose despite optimal diabetes therapy; and (3) Despite efforts at optimal glucose control, progressive secondary complications of diabetes, including retinopathy, neuropathy, or nephropathy Exclusion Criteria: Severe co-existing cardiac disease Active alcohol or substance abuse Psychiatric disorder making the subject not a suitable candidate for transplantation Active infection including hepatitis C, hepatitis B, HIV, or TB Any history of or current malignancies except squamous or basal skin cancer BMI > 28 kg/m2 or body weight > 85 kg at screening visit Positive fasting C-peptide response on assessment (2 positive results) Creatinine clearance < 80 mL/min/1.73 m2 Serum creatinine > 150 µmol/L Macroalbuminuria (urinary albumin excretion rate > 300 mg/24h) Baseline Hb < 105g/L in women, or < 130 g/L in men Baseline LFT's outside of normal range Untreated proliferative retinopathy Positive pregnancy test, intent for future pregnancy or male subjects' intent to procreate, failure to follow effective contraceptive measures, or presently breast feeding Previous transplant, or evidence of sensitization on PRA Insulin requirement > 1.0 IU/kg/day HbA1C > 0.12 Hyperlipidemia (fasting LDL cholesterol > 3.4 mmol/L, treated or untreated; and/or fasting triglycerides > 2.3 mmol/L) Under treatment for a medical condition requiring chronic use of steroids Use of coumadin or other anticoagulant therapy (except aspirin) or subject with PT INR > 1.5 Untreated Addison's disease Untreated Celiac disease Untreated thyroid disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
A.M. James Shapiro, MD, PhD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alberta - Clinical Islet Transplant Program
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G2C8
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
23438305
Citation
Gala-Lopez B, Kin T, O'Gorman D, Pepper AR, Senior P, Humar A, Shapiro AM. Microbial contamination of clinical islet transplant preparations is associated with very low risk of infection. Diabetes Technol Ther. 2013 Apr;15(4):323-7. doi: 10.1089/dia.2012.0297. Epub 2013 Feb 25.
Results Reference
derived

Learn more about this trial

Islet Transplantation Using Campath-1H and Infliximab Induction

We'll reach out to this number within 24 hrs